We are committed to working collaboratively with the FDA and because the agency did not suggest that additional Phase 3 studies may be needed to demonstrate the products safety and efficacy we believe we are well prepared to address the ir concerns  said Jan Mikkelsen Ascendis Pharmas President and CEO